SPI-1620
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SPI-1620, covering 2013-10-21 to 2013-10-21. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma [Phase 1]